Disorders of endocrine system, eye, respiratory system, skin, collagen disease, asthma, allergic disorder, and inflammatory disorder of musculoskeletal system.

Methylprednisolone sodium succinate is an injectable glucocorticoid that has about 1.25 times greater anti-inflammatory potency than prednisolone.

plasma protein binding: 78？ 3%. The drug is extensively metabolized, with 4.9？ 2.3% excreted unchanged in urine.

Hypersensitivity to the product, premature infants (preparations containing benzyl alcohol), systemic fungal infection, administration of live vaccines or attenuated live vaccine in patients receiving immunosuppressive doses.

C

minimal risk to the infant when used during breastfeeding.

Cataract, congestive heart failure, Cushing's syndrome, glaucoma, hyperglycemia, osteoporosis, primary adrenocortical insufficiency, pulmonary tuberculosis, raised intracranial pressure, seizure.

IV initial dosage 10-40 mg given over one to several minutes; high dose therapy, 30 mg/kg IV Q4H or Q6H for up to 48-72 hr are used for severe, acute conditions. Infuse large doses（≧500 mg）slowly (eg, over 30-60 min). IV for acute spinal cord injury 30 mg/kg over 15 min, begun within 8 hr of injury, followed 45 min later by a continuous IV infusion of 5.4 mg/kg/hr for 23 hr.

The reconstituted solution should be used within 24 hours